A phase 1/2, first in human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of AVZO-1418 as a single agent and in combination therapy in patients with locally advanced or metastatic solid tumors

16220AVZO-1418-1001-NCT07038343OpenA phase 1/2, first in human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of AVZO-1418 as a single agent and in combination therapy in patients with locally advanced or metastatic solid tumorsAVZO-1418-1001NCT07038343IndustrialAdultTreatmentI/IIMultipleLiu, StephenGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterPhase IOncology GroupLombardi Comprehensive Cancer Center (LCCC)2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>